World
Global Initiative To Demonstrate Operational Excellence in Nigeria for Metastatic Colorectal Cancer Patients
NORTHAMPTON, MA / ACCESS Newswire / October 29, 2025 / Bristol-Myers Squibb Company - Recently, the Innovative Cancer Medicines (ICM) initiative announced the enrollment of the first Nigerian patient in a pioneering demonstration project to provide ...
About this update from Bristol-myers Squibb Company
[{"type":"text","content":"NORTHAMPTON, MA / ACCESS Newswire / October 29, 2025 / Bristol-Myers Squibb Company - Recently, the Innovative Cancer Medicines (ICM) initiative announced the enrollment of the first Nigerian patient in a pioneering demonstration project to provide an immunotherapy drug used to treat cancer. The goal of the initiative is to develop an approach that explores sustainable and effective administration of innovative immuno-oncology therapies in low- and middle-income countries.","length":477,"tagName":"p"},{"type":"text","content":"The ICM initiative is a collaboration between the Clinton Health Access Initiative (CHAI) and the Parker Institute for Cancer Immunotherapy (PICI), along with Bristol Myers Squibb (BMS) and Roche, working with the National Hospital in Abuja, an oncology center in Nigeria recognized for its excellence.","length":302,"tagName":"p"},{"type":"text","content":"Low- and middle-income countries, particularly in sub-Saharan Africa, have historically faced challenges in accessing cancer treatments that have been available in high-income countries for decades. Yet Africa is one of the most affected regions globally, with the number of cancer deaths on the continent expected to double by 2040.1 Among the various cancers affecting the region, colorectal cancer represents a particular concern and is the focus of this initiative. In Nigeria alone, colorectal cancer accounts for approximately 6.4% of all cancers and is responsible for nearly 5,900 deaths a year.2","length":604,"tagName":"p"},{"type":"text","content":""This demonstration project will show to the world that we have institutions in Nigeria that are ready, with the right investments, to introduce and sustainably provide innovative diagnostics and medications," said Dr. Abubakar Bello, Chief Consultant, Clinical and Radiation Oncologist, National Hospital Abuja and the project's Principal Investigator.","length":367,"tagName":"p"},{"type":"text","content":""This milestone shows that Nigerian healthcare institutions can deliver world-class cancer care," said Dr. Adekunle Iziaq Salako, Hon. Minister of State for Health and Social Welfare, Nigeria. "This demonstration project will provide critical evidence on how advanced immunotherapy can be integrated into our health system."","length":344,"tagName":"p"},{"type":"text","conten...